Updated Jul 16, 2026
MELTZER LESLIE has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
Leslie Meltzer is the Chief Research and Development Officer at Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative therapies for diseases with high unmet medical needs. She has been involved in the company's efforts to develop treatments targeting the complement system.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 45.2K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 61.8K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 45.2K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 45.2K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | D — Derivative transaction | 22.6K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 22.6K | — | |
| 2026-05-14 | APLS | Apellis Pharmaceuticals, Inc. | J — Other acquisition / disposition | 107.0K | — | |
| 2026-01-30 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 45.2K | $0.00 | |
| 2025-08-26 | APLS | Apellis Pharmaceuticals, Inc. | A — Grant or award | 61.8K | $0.00 |
Leslie Meltzer is the Chief Research and Development Officer at Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative therapies for diseases with high unmet medical needs. She has been involved in the company's efforts to develop treatments targeting the complement system.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live MELTZER LESLIE profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.